Merck Reports Quarterly Loss Amid Cidara Charge, Sales Rise 5%
Merck & Co reported a first-quarter loss due to a $3.62 per share charge from its acquisition of Cidara Therapeutics, despite a 5% increase in sales driven by cancer and respiratory drugs. Revenue reached $16.3 billion, exceeding Wall Street estimates, and the company raised its 2026 profit forecast. Key products like Keytruda and Winrevair saw strong sales growth, while Januvia and Gardasil experienced declines.
Tickers: $MRK
Topics: Acquisition Charge Cidara Therapeutics Earnings Keytruda Loss Merck Revenue Growth Terns Pharmaceuticals